Heron Therapeutics initiated at Stifel

Heron Therapeutics initiated with a Buy at Stifel. Stifel analyst Derek Archila initiated Heron Therapeutics with a Buy rating and a price target of $55. The analyst expects the company’s HTX-011 to be approved for the prevention of postsurgical pain, becoming “the first product to receive an opioid sparing indication from the FDA”. Archila adds that shares could be driven higher amid the “continued discussion about potential legislation to unbundle branded non-opioid analgesic”.
https://thefly.com/landingPageNews.php?id=2790377